摘要
目的观察健脾益肺口服液治疗慢性阻塞性肺疾病(COPD)稳定期(肺脾气虚证)的临床疗效。方法将52例COPD稳定期患者随机分为治疗组和对照组。对照组24例采用西药常规治疗,治疗组28例在对照组治疗的基础上加用健脾益肺口服液治疗。连续治疗3个月,观察治疗前后证候积分、BODE指数(包括FEV1、6 min步行距离、呼吸困难量表评分、标准体重指数);测定治疗前后血清免疫球蛋白水平;同时观察2组患者疗1年内急性加重次数。结果治疗后两组患者证候积分均较治疗前降低,且治疗后治疗组证候积分低于对照组,差异具有统计学意义(P<0.05);治疗组临床控制及显效率(42.8%),高于对照组(20.8%),差异具有统计学意义(P<0.05);与治疗前比较,治疗组患者治疗后体重指数、呼吸困难量表评分及6 min步行距离明显增加,BODE指数降低,且优于对照组,差异有统计学意义(P<0.05);对照组治疗前后体重指数、呼吸困难量表评分、6 min步行距离及BODE指数差异无统计学意义(P>0.05);两组患者治疗后FEV1差异无统计学意义(P>0.05);治疗后治疗组血清IgG、IgA、IgM水平较治疗前提高,且IgG、IgA水平均高于对照组,差异具有统计学意义(P<0.05);1年内治疗组急性发作频率低于对照组,差异具有统计学意义(P<0.05)。结论健脾益肺口服液治疗COPD稳定期患者可以改善症状,增加运动耐量,提高机体免疫机能,减少急性发作次数。
Objective To observe the effect of Jianpi Yifei oral solution in chronic obstructive pulmonary disease（ COPD） in a stable condition with the syndrome of qi deficiency of both lung and spleen. Methods Totally 52 patients suffering from COPD in a stable condition with the syndrome of qi deficiency of both lung and spleen were randomized into treatment group of 28 cases and control group of 24 cases. Both two groups were adopted the conventional therapy,the treatment group was given Jianpi Yifei oral solution for 3 months and followed up for 1 year. TCM syndrome score,BODE index（ included BMI,FEV1% pred,MMRC and6MWD） and levels of plash immunoglobulin（ IgG,IgA,IgM） were compared between two groups. The aggravation times of COPD were observed throughout the whole follow-up period in two groups. Results After the treatment,the two groups improved clinical symptoms. In treatment group,TCM syndrome score were markedly decreased（ P 0. 05）,and the total efficiency of 42. 8% was better than 20. 8% of control group（ P 0. 05）; The parameters of BMI,6 MWT,MMRC dyspnea,BODE index and IgG,IgA were improver in treatment group than those in control group（ P 0. 05）. The FEV1 of both groups were without statistical difference（ P 0. 05）. The aggravation times of COPD were less in treatment group than those in control group（ P 0. 05）. Conclusion Jianpi Yifei oral solution is effective in the treat ment of COPD patients in stable stage,relieving symptoms,increasing excerie tolerance,regulating immunity function and decreasing aggravation times of COPD.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2014年第9期2178-2180,共3页
Lishizhen Medicine and Materia Medica Research
基金
南京市医学科技发展项目(No.YKK11042)
关键词
慢性阻塞性肺疾病
稳定期
健脾益肺口服液
BODE指数
Chronic obstructive pulmonary disease
Stable stage
Jianpi Yifei oral solution
BODE index
